CStone Pharmaceuticals
CSPHF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $4,774 | $2,106 | $1,300 | $2,903 |
| - Cash | $458 | $388 | $679 | $997 |
| + Debt | $391 | $356 | $335 | $363 |
| Enterprise Value | $4,707 | $2,074 | $955 | $2,270 |
| Revenue | $25 | $153 | $254 | $202 |
| % Growth | -83.8% | -39.8% | 25.6% | – |
| Gross Profit | -$46 | $68 | $172 | $151 |
| % Margin | -187.6% | 44.5% | 67.7% | 74.5% |
| EBITDA | -$133 | -$85 | $3 | -$342 |
| % Margin | -538.3% | -55.7% | 1.3% | -169.2% |
| Net Income | -$135 | -$107 | $16 | -$158 |
| % Margin | -546.4% | -69.9% | 6.2% | -78.1% |
| EPS Diluted | -0.1 | -0.084 | 0.012 | -0.124 |
| % Growth | -19.3% | -775.8% | 110% | – |
| Operating Cash Flow | $0 | -$156 | -$187 | -$248 |
| Capital Expenditures | $0 | $0 | $0 | -$0 |
| Free Cash Flow | $0 | -$156 | -$187 | -$248 |